cholesterol
Pharmaceutical News Roundup: Human Genome, Merck, Novartis
3:57PM 11/17/2010
Company News, Health Care, Merck, Human Genome, GlaxoSmithKline, Novartis, Stocks in the News
Here's a roundup of some of Wednesday's major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck's experimental heart drug appears to work well without side effects; and Novartis announced its plans for long-term growth.
AstraZeneca Shares Pop After Court Upholds Crestor's Patent Protection
10:10AM 6/30/2010
Company News, Health Care, Pfizer, Merck, Astrazeneca, Stocks in the News
AstraZeneca shares surged by almost 9% Tuesday after the company scored a win in court regarding the patent for its cholesterol treatment, Crestor. The ruling means that AstraZeneca won't have to worry about generic competition for its multibillion-dollar statin until 2016.
The FDA just gave AstraZeneca its blessings to add 6.5 million healthy people to its rolls of patients taking Crestor, a statin drug, as a preventative even if they do not have high cholesterol. That means health insurance will pay $3.50 per pill for all these millions of people until at least...
Inside Wall Street: Resverlogix Is a Baby Biotech That Could Grow Up Fast
7:30AM 3/19/2010
Company News, Technology, Columns, Investing, Pfizer, Merck, Novartis
If promising early results of its cholesterol-busting drug RVX-208 get supported in larger clinical trials, it could put this young company on the map in a big way. A partnership with a major drugmaker is a very strong possibility.
Wider Approval for Crestor Brings Out Cynics
2:50PM 2/10/2010
Earlier this week, AstraZeneca's widely used cholesterol-lowering drug Crestor was approved by the U.S. Food and Drug Administration for use in people with normal cholesterol to prevent heart attacks and strokes. The approval could lead to a much bigger market for Crestor, but has also led to a number of critics questioning the decision.
Crestor Backed by FDA for Patients With Normal Cholesterol Levels
7:30PM 12/16/2009
AstraZeneca scored a win on Tuesday, when a Food and Drug Administration advisory panel recommended broader use of Crestor, the company's cholesterol-lowering drug. The panel recommended that those with low cholesterol use the drug, following studies finding that Crestor reduces the risk of heart disease even in those with normal cholesterol levels.
Get a free, customized vitamin plan based specifically on your health when you click on the image at right. No purchase is required -- though they gently suggest you buy vitamins -- so this is useful if you already take vitamins or are interested in starting.
More Stories
Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.11 | -0.08 -0.92% | 127.06M | |
| 2.20 | +0.26 +13.40% | 82.46M | |
| 29.61 | -2.38 -7.44% | 19.63M | |
| 18.84 | -0.29 -1.52% | 18.58M |
% Gainers
| 30.94 | +7.04 +29.46% | 10.42M | |
| 87.49 | +11.10 +14.53% | 5.78M | |
| 10.70 | +1.30 +13.83% | 2.46M | |
| 2.20 | +0.26 +13.40% | 82.46M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Stocks fall sharply as Greek deal is held up
- Turbo-traders take Bank of America for a ride
- Donald Trump blasts plans for Scottish wind...
- Greece caught between protests, austerity...
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- NYSE Euronext profit down on blocked merger...
- Obama call for manufacturing revival a tough...
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
- Morning Wire — US Stock-Index Futures Down Sharply
- Alcatel-Lucent Pulls a Rabbit Out of Its Hat on Earnings (ALU)
Follow Us
